David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

An innovative blood cancer treatment regimen could extend remission by seven months on average, according to a clinical trial ...

The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules ...

Final overall survival results from the Phase III APHINITY trial show a 17% reduction in the risk of death at 10 years for ...